Neuralink's second brain implant shows promise as the company aims to enhance the quality of life for individuals with spinal ...

Blindsight, the experimental vision-restoring implant by Elon Musk’s brain-chip startup, Neuralink, has received the U.S. Food and Drug Administration’s (FDA) "breakthrough device" designation ...

Elon Musk's Neuralink has been awarded breakthrough status from the FDA for an implantable chip – dubbed Blindsight – that promises to restore the sight of people with vision impairment.

Elon Musk's Neuralink has been awarded breakthrough status from the FDA for an implantable chip – dubbed Blindsight – that promises to restore the sight of people with vision impairment.

In February 2024, the U.S. FDA approved Aurlumyn (iloprost), an injectable vasodilator treatment that is the first ever to be approved for the treatment of severe frostbite. This approval was ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding ...

Science Corporation, a biotech startup launched by a Neuralink cofounder who left the company, claims that's achieved a ...

Tirzepatide was first approved by the Food and Drug Administration (FDA) in 2022 and has no generic versions on the market. But when the drug was declared to be in shortage in December that same ...

An FDA spokesperson responded that the Federal, Food, Drug, and Cosmetic Act does not give the FDA authority to follow through on some of the recommendations mentioned in the article. The article ...

The FDA has agreed to review its decision to remove Eli Lilly’s LLY tirzepatide — the active ingredient used in diabetes drug Mounjaro and obesity drug Zepbound — from its shortage list.